

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>AISLING CAPITAL III LP</u> (Last) (First) (Middle) 888 SEVENTH AVENUE, 12TH FLOOR (Street) NEW YORK NY 10106 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>T2 Biosystems, Inc. [TTOO]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 12/09/2015	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/09/2015		P		307,692	A	\$9.75	2,830,992	I	See footnote ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)					

1. Name and Address of Reporting Person*
AISLING CAPITAL III LP
 (Last) (First) (Middle)
 888 SEVENTH AVENUE, 12TH FLOOR
 (Street)
 NEW YORK NY 10106
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Aisling Capital Partners III LP
 (Last) (First) (Middle)
 AISLING CAPITAL LLC
 888 SEVENTH AVENUE 12TH FLOOR
 (Street)
 NEW YORK NY 10106
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Aisling Capital Partners III LLC
 (Last) (First) (Middle)
 AISLING CAPITAL LLC
 888 SEVENTH AVENUE 12TH FLOOR

(Street)
NEW YORK NY 10106

(City) (State) (Zip)

1. Name and Address of Reporting Person*

ELMS STEVE

(Last) (First) (Middle)

888 SEVENTH AVENUE
12TH FLOOR

(Street)
NEW YORK NY 10106

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SCHIFF ANDREW N

(Last) (First) (Middle)

888 SEVENTH AVENUE, 12TH FLOOR

(Street)
NEW YORK NY 10106

(City) (State) (Zip)

1. Name and Address of Reporting Person*

Purcell Dennis J

(Last) (First) (Middle)

888 SEVENTH AVENUE, 12TH FLOOR

(Street)
NEW YORK NY 10106

(City) (State) (Zip)

Explanation of Responses:

1. The reportable securities are owned directly by Aisling Capital III, LP ("Aisling"), and held indirectly by Aisling Capital Partners III, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners III LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners and the Managers share voting and dispositive power over the shares directly held by Aisling.

[See Signatures on Exhibit 99.1 12/09/2015](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FORM 4 JOINT FILER INFORMATION

Names of Joint Filers:

Aisling Capital III, LP
Aisling Capital Partners III, LP
Aisling Capital Partners III LLC
Steve Elms
Andrew N. Schiff, M.D.
Dennis J. Purcell

Address of Joint Filers:

c/o Aisling Capital Partners LLC
888 Seventh Avenue
New York, NY 10106

Designated Filer: Aisling Capital III, LP
Issuer and Ticker Symbol: T2 Biosystems, Inc. [TTOO]
Date of Event: December 9, 2015

Signatures of Joint Filers:

 AISLING CAPITAL III, LP

By: Aisling Capital Partners III, LP
General Partner

By: Aisling Capital Partners III LLC
General Partner

By: /s/ Lloyd Appel
Name: Lloyd Appel
Title: CFO

 AISLING CAPITAL PARTNERS III, LP

By: Aisling Capital Partners III LLC
General Partner

By: /s/ Lloyd Appel
Name: Lloyd Appel
Title: CFO

 AISLING CAPITAL PARTNERS III LLC

By: /s/ Lloyd Appel
Name: Lloyd Appel
Title: CFO

/s/ Steve Elms
Steve Elms

/s/ Andrew Schiff
Andrew Schiff

/s/ Dennis Purcell
Dennis Purcell
